Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses
January 27, 2015 01:00 ET
|
NOVARTIS FINANCE S.A.
Net sales grew in FY 2014, with strong core[1] margin expansion Net sales increased 1% (+3% cc[1])[2] to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7...
Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, the leading cause of bacterial meningitis in the US
January 25, 2015 16:22 ET
|
NOVARTIS FINANCE S.A.
With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexible...
Novartis' heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe[1]
November 28, 2014 01:15 ET
|
NOVARTIS FINANCE S.A.
Decision by EU review body could speed access to LCZ696 for HFrEF patients in the EU LCZ696 is the first investigational cardiovascular drug to be granted accelerated assessment, shortening the...
Novartis Cosentyx(TM) receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients
November 21, 2014 01:15 ET
|
NOVARTIS FINANCE S.A.
Cosentyx (secukinumab, formerly AIN457) is recommended as first-line systemic therapy for the treatment of moderate-to-severe plaque psoriasis in adult patients in Europe In Phase III studies,...
Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients[1],[2]
November 17, 2014 16:45 ET
|
NOVARTIS FINANCE S.A.
New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus...
Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter
October 28, 2014 02:00 ET
|
NOVARTIS FINANCE S.A.
Net sales up 4% (+5% cc)[1] in Q3, with operating margin increase across Q3 and 9M Net sales of USD 14.7 billion grew 4% (+5% cc[2]) in Q3 Strong operating income growth in Q3 of 14% (+18% cc)...
Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million
October 26, 2014 17:00 ET
|
NOVARTIS FINANCE S.A.
CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the...
Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine
October 23, 2014 01:15 ET
|
NOVARTIS FINANCE S.A.
Secukinumab is the first selective IL-17A inhibitor to meet primary endpoint in two pivotal Phase III studies showing improvement in active ankylosing spondylitis (AS) patients' symptoms versus...
Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)
October 15, 2014 17:00 ET
|
NOVARTIS FINANCE S.A.
Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL019[1] Largest...
Changes to the Novartis Executive Committee after expected completion of portfolio transactions
October 08, 2014 01:00 ET
|
NOVARTIS FINANCE S.A.
Three members of the Executive Committee of Novartis to leave company, following completion of portfolio transactions expected to close in first half 2015 Basel, October 8, 2014 - Novartis...